170 related articles for article (PubMed ID: 8631589)
21. HPV primary screening for cervical cancer: more pain than protection.
Davey DD; Armenti CA
Diagn Cytopathol; 2000 Jun; 22(6):333-5. PubMed ID: 10820524
[No Abstract] [Full Text] [Related]
22. Cervical cancer screening by high risk HPV testing in routine practice: results at one year recall of high risk HPV-positive and cytology-negative women.
Del Mistro A; Frayle H; Ferro A; Callegaro S; Del Sole A; Stomeo A; Cirillo E; Fedato C; Pagni S; Barzon L; Zorzi M;
J Med Screen; 2014 Mar; 21(1):30-7. PubMed ID: 24488593
[TBL] [Abstract][Full Text] [Related]
23. Primary HPV screening for cervical cancer.
Bhatla N; Singhal S
Best Pract Res Clin Obstet Gynaecol; 2020 May; 65():98-108. PubMed ID: 32291178
[TBL] [Abstract][Full Text] [Related]
24. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women.
Clavel C; Masure M; Bory JP; Putaud I; Mangeonjean C; Lorenzato M; Nazeyrollas P; Gabriel R; Quereux C; Birembaut P
Br J Cancer; 2001 Jun; 84(12):1616-23. PubMed ID: 11401314
[TBL] [Abstract][Full Text] [Related]
25. Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy.
Schneider A; Hoyer H; Lotz B; Leistritza S; Kühne-Heid R; Nindl I; Müller B; Haerting J; Dürst M
Int J Cancer; 2000 Nov; 89(6):529-34. PubMed ID: 11102899
[TBL] [Abstract][Full Text] [Related]
26. Extended duration of the detectable stage by adding HPV test in cervical cancer screening.
van den Akker-van Marie ME; van Ballegooijen M; Rozendaal L; Meijer CJ; Habbema JD
Br J Cancer; 2003 Nov; 89(10):1830-3. PubMed ID: 14612887
[TBL] [Abstract][Full Text] [Related]
27. [Human papillomavirus and screening for cervical cancer: state of art and prospects].
Meijer CJ; Rozendaal L; Voorhorst FJ; Verheijen R; Helmerhorst TJ; Walboomers JM
Ned Tijdschr Geneeskd; 2000 Aug; 144(35):1675-9. PubMed ID: 10981235
[TBL] [Abstract][Full Text] [Related]
28. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
Cox JT;
Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
[TBL] [Abstract][Full Text] [Related]
29. PCR-reverse dot blot human papillomavirus genotyping as a primary screening test for cervical cancer in a hospital-based cohort.
Kang Y; Sun P; Mao X; Dong B; Ruan G; Chen L
J Gynecol Oncol; 2019 May; 30(3):e29. PubMed ID: 30887754
[TBL] [Abstract][Full Text] [Related]
30. Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions.
Sellors JW; Lorincz AT; Mahony JB; Mielzynska I; Lytwyn A; Roth P; Howard M; Chong S; Daya D; Chapman W; Chernesky M
CMAJ; 2000 Sep; 163(5):513-8. PubMed ID: 11006761
[TBL] [Abstract][Full Text] [Related]
31. The Clinical and Economic Benefits of Co-Testing Versus Primary HPV Testing for Cervical Cancer Screening: A Modeling Analysis.
Felix JC; Lacey MJ; Miller JD; Lenhart GM; Spitzer M; Kulkarni R
J Womens Health (Larchmt); 2016 Jun; 25(6):606-16. PubMed ID: 27023044
[TBL] [Abstract][Full Text] [Related]
32. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy.
Kim JJ; Wright TC; Goldie SJ
J Natl Cancer Inst; 2005 Jun; 97(12):888-95. PubMed ID: 15956650
[TBL] [Abstract][Full Text] [Related]
34. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test.
Wright TC; Stoler MH; Behrens CM; Sharma A; Zhang G; Wright TL
Gynecol Oncol; 2015 Feb; 136(2):189-97. PubMed ID: 25579108
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus screening and cervical cancer prevention.
Sasieni PD
J Am Med Womens Assoc (1972); 2000; 55(4):216-9. PubMed ID: 10935355
[TBL] [Abstract][Full Text] [Related]
36. Detection of cervical precancer and cancer in a hospital population; benefits of testing for human papillomavirus.
Dalstein V; Riethmuller D; Sautière JL; Prétet JL; Kantelip B; Schaal JP; Mougin C
Eur J Cancer; 2004 May; 40(8):1225-32. PubMed ID: 15110887
[TBL] [Abstract][Full Text] [Related]
37. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
[TBL] [Abstract][Full Text] [Related]
38. A new generation of studies of human papillomavirus DNA testing in cervical cancer screening.
Franco EL
J Natl Cancer Inst; 2009 Dec; 101(23):1600-1. PubMed ID: 19903806
[No Abstract] [Full Text] [Related]
39. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
[TBL] [Abstract][Full Text] [Related]
40. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
